Resultado de la búsqueda
5 búsqueda de la palabra clave 'Pharmacology'
Refinar búsqueda Generar rss de la búsqueda
Link de la búsqueda
Título : Modeling in Biopharmaceutics, Pharmacokinetics, and Pharmacodynamics : Homogeneous and Heterogeneous Approaches Tipo de documento: documento electrónico Autores: Panos Macheras ; SpringerLink (Online service) ; Athanassios Iliadis Editorial: New York, NY : Springer New York Fecha de publicación: 2006 Colección: Interdisciplinary Applied Mathematics, ISSN 0939-6047 num. 30 Número de páginas: XX, 444 p Il.: online resource ISBN/ISSN/DL: 978-0-387-31910-0 Idioma : Inglés (eng) Palabras clave: Mathematics Pharmacology Biochemistry Applied mathematics Engineering Biomathematics Biophysics Biological physics Biomedical engineering Mathematical and Computational Biology Pharmacology/Toxicology Physics Biochemistry, general Applications of Clasificación: 51 Matemáticas Resumen: The state of the art in Biopharmaceutics, Pharmacokinetics, and Pharmacodynamics Modeling is presented in this book. It shows how advanced physical and mathematical methods can expand classical models in order to cover heterogeneous drug-biological processes and therapeutic effects in the body. The book is divided into four parts; the first deals with the fundamental principles of fractals, diffusion and nonlinear dynamics; the second with drug dissolution, release, and absorption; the third with empirical, compartmental, and stochastic pharmacokinetic models, and the fourth mainly with nonclassical aspects of pharmacodynamics. The classical models that have relevance and application to these sciences are also considered throughout. Many examples are used to illustrate the intrinsic complexity of drug administration related phenomena in the human, justifying the use of advanced modeling methods. This timely and useful book will appeal to graduate students and researchers in pharmacology, pharmaceutical sciences, bioengineering, and physiology Nota de contenido: Basic Concepts -- The Geometry of Nature -- Diffusion and Kinetics -- Nonlinear Dynamics -- Modeling in Biopharmaceutics -- Drug Release -- Drug Dissolution -- Oral Drug Absorption -- Modeling in Pharmacokinetics -- Empirical Models -- Deterministic Compartmental Models -- Stochastic Compartmental Models -- Modeling in Pharmacodynamics -- Classical Pharmacodynamics -- Nonclassical Pharmacodynamics En línea: http://dx.doi.org/10.1007/0-387-31910-7 Link: https://biblioteca.cunef.edu/gestion/catalogo/index.php?lvl=notice_display&id=34793 Modeling in Biopharmaceutics, Pharmacokinetics, and Pharmacodynamics : Homogeneous and Heterogeneous Approaches [documento electrónico] / Panos Macheras ; SpringerLink (Online service) ; Athanassios Iliadis . - New York, NY : Springer New York, 2006 . - XX, 444 p : online resource. - (Interdisciplinary Applied Mathematics, ISSN 0939-6047; 30) .
ISBN : 978-0-387-31910-0
Idioma : Inglés (eng)
Palabras clave: Mathematics Pharmacology Biochemistry Applied mathematics Engineering Biomathematics Biophysics Biological physics Biomedical engineering Mathematical and Computational Biology Pharmacology/Toxicology Physics Biochemistry, general Applications of Clasificación: 51 Matemáticas Resumen: The state of the art in Biopharmaceutics, Pharmacokinetics, and Pharmacodynamics Modeling is presented in this book. It shows how advanced physical and mathematical methods can expand classical models in order to cover heterogeneous drug-biological processes and therapeutic effects in the body. The book is divided into four parts; the first deals with the fundamental principles of fractals, diffusion and nonlinear dynamics; the second with drug dissolution, release, and absorption; the third with empirical, compartmental, and stochastic pharmacokinetic models, and the fourth mainly with nonclassical aspects of pharmacodynamics. The classical models that have relevance and application to these sciences are also considered throughout. Many examples are used to illustrate the intrinsic complexity of drug administration related phenomena in the human, justifying the use of advanced modeling methods. This timely and useful book will appeal to graduate students and researchers in pharmacology, pharmaceutical sciences, bioengineering, and physiology Nota de contenido: Basic Concepts -- The Geometry of Nature -- Diffusion and Kinetics -- Nonlinear Dynamics -- Modeling in Biopharmaceutics -- Drug Release -- Drug Dissolution -- Oral Drug Absorption -- Modeling in Pharmacokinetics -- Empirical Models -- Deterministic Compartmental Models -- Stochastic Compartmental Models -- Modeling in Pharmacodynamics -- Classical Pharmacodynamics -- Nonclassical Pharmacodynamics En línea: http://dx.doi.org/10.1007/0-387-31910-7 Link: https://biblioteca.cunef.edu/gestion/catalogo/index.php?lvl=notice_display&id=34793 Ejemplares
Signatura Medio Ubicación Sub-localización Sección Estado ningún ejemplar
Título : Dose Finding in Drug Development Tipo de documento: documento electrónico Autores: SpringerLink (Online service) ; Naitee Ting Editorial: New York, NY : Springer New York Fecha de publicación: 2006 Colección: Statistics for Biology and Health, ISSN 1431-8776 Número de páginas: XIV, 248 p Il.: online resource ISBN/ISSN/DL: 978-0-387-33706-7 Idioma : Inglés (eng) Palabras clave: Medicine Pharmacology Statistics Biomedicine Pharmacology/Toxicology for Life Sciences, Medicine, Health Sciences Clasificación: 51 Matemáticas Resumen: When you go to the pharmacy and fill a prescription, have you ever wondered if the dose of the medication is right for you? Can the dose be too low so that the drug will not work? Can the dose be too high that it may cause some potential problem? How do people learn about dosing information? This book answers some of these questions. Dosing information on the drug label is based on discussion and agreement between the pharmaceutical manufacturer and the drug regulatory agency. A drug label is a high level summary of results obtained from many scientific experiments. Scientists with biological, chemical, medical, or statistical background working in the pharmaceutical industry designed and executed these experiments to obtain information to help understand the dosing information. This book introduces the drug development process, the design and analysis of clinical trials. Many of the discussions are based on applications of statistical methods in the design and analysis of dose response studies. Although the book is prepared mainly for statisticians/biostatisticians, it also serves as a useful reference to a variety of professionals working for the pharmaceutical industry. The potential readers include pharmacokienticists, clinical scientists, clinical pharmacologists, pharmacists, project managers, pharmaceutical scientists, clinicians, programmers, data managers, regulatory specialists, and study report writers. This book is also a good reference for professionals working in a drug regulatory environment, for example, the FDA. Scientists and/or reviewers from both U.S. and foreign drug regulatory agencies can benefit greatly from this book. In addition, statistical and medical professionals in academia may find this book helpful in understanding the drug development process and practical concerns in selecting doses for a new drug. Naitee Ting received his Ph. D. in statistics from Colorado State University in 1987 and joined Pfizer Research right after obtaining his Ph. D. Dr. Ting is currently an Associate Director of Biostatistics in Pfizer Global Research and Development, supporting clinical development of new drugs. He has over 18 years of experiences in designing and analyzing late phase clinical trials. During his tenure at Pfizer, Dr. Ting has published more than 20 statistical papers in peer-reviewed journals and book chapters. He has also taught clinical trials courses at the University of Connecticut and University of Rhode Island Nota de contenido: and New Drug Development Process -- Dose Finding Based on Preclinical Studies -- Dose-Finding Studies in Phase I and Estimation of Maximally Tolerated Dose -- Dose-Finding in Oncology—Nonparametric Methods -- Dose Finding in Oncology—Parametric Methods -- Dose Response: Pharmacokinetic–Pharmacodynamic Approach -- General Considerations in Dose–Response Study Designs -- Clinical Trial Simulation—A Case Study Incorporating Efficacy and Tolerability Dose Response -- Analysis of Dose–Response Studies—Emax Model -- Analysis of Dose–Response Studies—Modeling Approaches -- Multiple Comparison Procedures in Dose Response Studies -- Partitioning Tests in Dose–Response Studies with Binary Outcomes -- Analysis of Dose–Response Relationship Based on Categorical Outcomes -- Power and Sample Size for Dose Response Studies En línea: http://dx.doi.org/10.1007/0-387-33706-7 Link: https://biblioteca.cunef.edu/gestion/catalogo/index.php?lvl=notice_display&id=34805 Dose Finding in Drug Development [documento electrónico] / SpringerLink (Online service) ; Naitee Ting . - New York, NY : Springer New York, 2006 . - XIV, 248 p : online resource. - (Statistics for Biology and Health, ISSN 1431-8776) .
ISBN : 978-0-387-33706-7
Idioma : Inglés (eng)
Palabras clave: Medicine Pharmacology Statistics Biomedicine Pharmacology/Toxicology for Life Sciences, Medicine, Health Sciences Clasificación: 51 Matemáticas Resumen: When you go to the pharmacy and fill a prescription, have you ever wondered if the dose of the medication is right for you? Can the dose be too low so that the drug will not work? Can the dose be too high that it may cause some potential problem? How do people learn about dosing information? This book answers some of these questions. Dosing information on the drug label is based on discussion and agreement between the pharmaceutical manufacturer and the drug regulatory agency. A drug label is a high level summary of results obtained from many scientific experiments. Scientists with biological, chemical, medical, or statistical background working in the pharmaceutical industry designed and executed these experiments to obtain information to help understand the dosing information. This book introduces the drug development process, the design and analysis of clinical trials. Many of the discussions are based on applications of statistical methods in the design and analysis of dose response studies. Although the book is prepared mainly for statisticians/biostatisticians, it also serves as a useful reference to a variety of professionals working for the pharmaceutical industry. The potential readers include pharmacokienticists, clinical scientists, clinical pharmacologists, pharmacists, project managers, pharmaceutical scientists, clinicians, programmers, data managers, regulatory specialists, and study report writers. This book is also a good reference for professionals working in a drug regulatory environment, for example, the FDA. Scientists and/or reviewers from both U.S. and foreign drug regulatory agencies can benefit greatly from this book. In addition, statistical and medical professionals in academia may find this book helpful in understanding the drug development process and practical concerns in selecting doses for a new drug. Naitee Ting received his Ph. D. in statistics from Colorado State University in 1987 and joined Pfizer Research right after obtaining his Ph. D. Dr. Ting is currently an Associate Director of Biostatistics in Pfizer Global Research and Development, supporting clinical development of new drugs. He has over 18 years of experiences in designing and analyzing late phase clinical trials. During his tenure at Pfizer, Dr. Ting has published more than 20 statistical papers in peer-reviewed journals and book chapters. He has also taught clinical trials courses at the University of Connecticut and University of Rhode Island Nota de contenido: and New Drug Development Process -- Dose Finding Based on Preclinical Studies -- Dose-Finding Studies in Phase I and Estimation of Maximally Tolerated Dose -- Dose-Finding in Oncology—Nonparametric Methods -- Dose Finding in Oncology—Parametric Methods -- Dose Response: Pharmacokinetic–Pharmacodynamic Approach -- General Considerations in Dose–Response Study Designs -- Clinical Trial Simulation—A Case Study Incorporating Efficacy and Tolerability Dose Response -- Analysis of Dose–Response Studies—Emax Model -- Analysis of Dose–Response Studies—Modeling Approaches -- Multiple Comparison Procedures in Dose Response Studies -- Partitioning Tests in Dose–Response Studies with Binary Outcomes -- Analysis of Dose–Response Relationship Based on Categorical Outcomes -- Power and Sample Size for Dose Response Studies En línea: http://dx.doi.org/10.1007/0-387-33706-7 Link: https://biblioteca.cunef.edu/gestion/catalogo/index.php?lvl=notice_display&id=34805 Ejemplares
Signatura Medio Ubicación Sub-localización Sección Estado ningún ejemplar
Título : evaluating clinical research : All that glitters is not gold Tipo de documento: documento electrónico Autores: Bengt D. Furberg ; SpringerLink (Online service) ; Curt D. Furberg Editorial: New York, NY : Springer New York Fecha de publicación: 2007 Número de páginas: V, 165 p Il.: online resource ISBN/ISSN/DL: 978-0-387-72899-5 Idioma : Inglés (eng) Palabras clave: Statistics Pharmacology Medical research Quality of life for Life Sciences, Medicine, Health Sciences Research Pharmacology/Toxicology Clasificación: 51 Matemáticas Resumen: The objective of this book is to make its readers better informed and more critical consumers of clinical research to help them recognize the strengths and the weaknesses of scientific publications. In doing so, the reader will be able to distinguish patient-important and methodologically sound studies from those having limitations in design, conduct and interpretation. There are no prerequisites for reading this book. The text is basic and has no statistical formulas. Key take-home messages are listed at the end of each chapter. The large number of cartoons has two purposes: First, to make the text easier to read and generate a few laughs and, second, to underscore specific points, sometimes in a provocative way. Bengt D. Furberg, MD, PhD is board-certified in internal medicine. After spending a decade as medical director in the pharmaceutical industry, he now serves as medical consultant, evaluating the safety and efficacy of pharmaceutical products and medical devices and promoting evidence-based medicine. His brother, Curt D. Furberg, MD, PhD, is Professor in the Division of Public Health Sciences, Wake Forest University School of Medicine, Winston-Salem, NC, USA. After arriving in the United States from Sweden, he worked at the National Heart, Lung, and Blood Institute of the National Institutes of Health for 12 years. He is co-author of Fundamentals of Clinical Trials with Lawrence M. Friedman and David L. DeMets. His areas of interest are clinical trials, evidence-based medicine and drug safety. The authors have acquired much of their knowledge about clinical studies through the "trial and error" method. Thus, they have personal experience with many of the problems they describe Nota de contenido: What is the purpose of this book? -- Why is benefit-to-harm balance essential to treatment decisions? -- What are the strengths of randomized controlled clinical trials? -- What are the weaknesses of randomized controlled clinical trials? -- Do meta-analyses provide the ultimate truth? -- What are the strengths of observational studies? -- What are the weaknesses of observational studies? -- Were the scientific questions stated in advance? -- Were the treatment groups comparable initially? -- Why is blinding/masking so important? -- How is symptomatic improvement measured? -- Is it really possible to assess quality of life? -- What is the value of biologic markers in drug evaluation? -- How are adverse drug reactions measured? -- How representative are study subjects in clinical trials? -- What happened to the study subjects who disappeared from the analysis? -- How reliable are active-control trials? -- How informative are composite outcomes? -- Do changes in biologic markers predict clinical benefit? -- How trustworthy are the authors? -- Does publication in a reputable scientific journal guarantee quality? -- Is it necessary to be a biostatistician to interpret scientific data? -- Are all drugs of a class interchangeable? -- How much confidence can be placed on economic analysis? -- How should I handle the massive flow of information? -- How well is research translated into clinical care? En línea: http://dx.doi.org/10.1007/978-0-387-72899-5 Link: https://biblioteca.cunef.edu/gestion/catalogo/index.php?lvl=notice_display&id=34535 evaluating clinical research : All that glitters is not gold [documento electrónico] / Bengt D. Furberg ; SpringerLink (Online service) ; Curt D. Furberg . - New York, NY : Springer New York, 2007 . - V, 165 p : online resource.
ISBN : 978-0-387-72899-5
Idioma : Inglés (eng)
Palabras clave: Statistics Pharmacology Medical research Quality of life for Life Sciences, Medicine, Health Sciences Research Pharmacology/Toxicology Clasificación: 51 Matemáticas Resumen: The objective of this book is to make its readers better informed and more critical consumers of clinical research to help them recognize the strengths and the weaknesses of scientific publications. In doing so, the reader will be able to distinguish patient-important and methodologically sound studies from those having limitations in design, conduct and interpretation. There are no prerequisites for reading this book. The text is basic and has no statistical formulas. Key take-home messages are listed at the end of each chapter. The large number of cartoons has two purposes: First, to make the text easier to read and generate a few laughs and, second, to underscore specific points, sometimes in a provocative way. Bengt D. Furberg, MD, PhD is board-certified in internal medicine. After spending a decade as medical director in the pharmaceutical industry, he now serves as medical consultant, evaluating the safety and efficacy of pharmaceutical products and medical devices and promoting evidence-based medicine. His brother, Curt D. Furberg, MD, PhD, is Professor in the Division of Public Health Sciences, Wake Forest University School of Medicine, Winston-Salem, NC, USA. After arriving in the United States from Sweden, he worked at the National Heart, Lung, and Blood Institute of the National Institutes of Health for 12 years. He is co-author of Fundamentals of Clinical Trials with Lawrence M. Friedman and David L. DeMets. His areas of interest are clinical trials, evidence-based medicine and drug safety. The authors have acquired much of their knowledge about clinical studies through the "trial and error" method. Thus, they have personal experience with many of the problems they describe Nota de contenido: What is the purpose of this book? -- Why is benefit-to-harm balance essential to treatment decisions? -- What are the strengths of randomized controlled clinical trials? -- What are the weaknesses of randomized controlled clinical trials? -- Do meta-analyses provide the ultimate truth? -- What are the strengths of observational studies? -- What are the weaknesses of observational studies? -- Were the scientific questions stated in advance? -- Were the treatment groups comparable initially? -- Why is blinding/masking so important? -- How is symptomatic improvement measured? -- Is it really possible to assess quality of life? -- What is the value of biologic markers in drug evaluation? -- How are adverse drug reactions measured? -- How representative are study subjects in clinical trials? -- What happened to the study subjects who disappeared from the analysis? -- How reliable are active-control trials? -- How informative are composite outcomes? -- Do changes in biologic markers predict clinical benefit? -- How trustworthy are the authors? -- Does publication in a reputable scientific journal guarantee quality? -- Is it necessary to be a biostatistician to interpret scientific data? -- Are all drugs of a class interchangeable? -- How much confidence can be placed on economic analysis? -- How should I handle the massive flow of information? -- How well is research translated into clinical care? En línea: http://dx.doi.org/10.1007/978-0-387-72899-5 Link: https://biblioteca.cunef.edu/gestion/catalogo/index.php?lvl=notice_display&id=34535 Ejemplares
Signatura Medio Ubicación Sub-localización Sección Estado ningún ejemplar Making Medicines in Africa / Maureen Mackintosh ; SpringerLink (Online service) ; Geoffrey Banda ; Paula Tibandebage ; Watu Wamae (2016)
Título : Making Medicines in Africa : The Political Economy of Industrializing for Local Health Tipo de documento: documento electrónico Autores: Maureen Mackintosh ; SpringerLink (Online service) ; Geoffrey Banda ; Paula Tibandebage ; Watu Wamae Editorial: London : Palgrave Macmillan UK Fecha de publicación: 2016 Otro editor: Imprint: Palgrave Macmillan Colección: International Political Economy Series Número de páginas: XXI, 334 p Il.: online resource ISBN/ISSN/DL: 978-1-137-54647-0 Idioma : Inglés (eng) Palabras clave: Ethnology Africa Political economy International relations Pharmacology economics Economic policy Economics Policy Relations Pharmacology/Toxicology Economy African Culture Clasificación: 330 Economía en general Resumen: This book is open access under a CC-BY license. The importance of the pharmaceutical industry in Sub-Saharan Africa, its claim to policy priority, is rooted in the vast unmet health needs of the sub-continent. Making Medicines in Africa is a collective endeavour, by a group of contributors with a strong African and more broadly Southern presence, to find ways to link technological development, investment and industrial growth in pharmaceuticals to improve access to essential good quality medicines, as part of moving towards universal access to competent health care in Africa. The authors aim to shift the emphasis in international debate and initiatives towards sustained Africa-based and African-led initiatives to tackle this huge challenge. Without the technological, industrial, intellectual, organisational and research-related capabilities associated with competent pharmaceutical production, and without policies that pull the industrial sectors towards serving local health needs, the African sub-continent cannot generate the resources to tackle its populations' needs and demands. Research for this book has been selected as one of the 20 best examples of the impact of UK research on development. See http://www.ukcds.org.uk/the-global-impact-of-uk-research for further details En línea: http://dx.doi.org/10.1007/978-1-137-54647-0 Link: https://biblioteca.cunef.edu/gestion/catalogo/index.php?lvl=notice_display&id=42029 Making Medicines in Africa : The Political Economy of Industrializing for Local Health [documento electrónico] / Maureen Mackintosh ; SpringerLink (Online service) ; Geoffrey Banda ; Paula Tibandebage ; Watu Wamae . - London : Palgrave Macmillan UK : Imprint: Palgrave Macmillan, 2016 . - XXI, 334 p : online resource. - (International Political Economy Series) .
ISBN : 978-1-137-54647-0
Idioma : Inglés (eng)
Palabras clave: Ethnology Africa Political economy International relations Pharmacology economics Economic policy Economics Policy Relations Pharmacology/Toxicology Economy African Culture Clasificación: 330 Economía en general Resumen: This book is open access under a CC-BY license. The importance of the pharmaceutical industry in Sub-Saharan Africa, its claim to policy priority, is rooted in the vast unmet health needs of the sub-continent. Making Medicines in Africa is a collective endeavour, by a group of contributors with a strong African and more broadly Southern presence, to find ways to link technological development, investment and industrial growth in pharmaceuticals to improve access to essential good quality medicines, as part of moving towards universal access to competent health care in Africa. The authors aim to shift the emphasis in international debate and initiatives towards sustained Africa-based and African-led initiatives to tackle this huge challenge. Without the technological, industrial, intellectual, organisational and research-related capabilities associated with competent pharmaceutical production, and without policies that pull the industrial sectors towards serving local health needs, the African sub-continent cannot generate the resources to tackle its populations' needs and demands. Research for this book has been selected as one of the 20 best examples of the impact of UK research on development. See http://www.ukcds.org.uk/the-global-impact-of-uk-research for further details En línea: http://dx.doi.org/10.1007/978-1-137-54647-0 Link: https://biblioteca.cunef.edu/gestion/catalogo/index.php?lvl=notice_display&id=42029 Ejemplares
Signatura Medio Ubicación Sub-localización Sección Estado ningún ejemplar
Título : Nonlinear Regression with R Tipo de documento: documento electrónico Autores: SpringerLink (Online service) ; Christian Ritz ; Jens Carl Streibig Editorial: New York, NY : Springer New York Fecha de publicación: 2008 Colección: Use R Número de páginas: XII, 148 p Il.: online resource ISBN/ISSN/DL: 978-0-387-09616-2 Idioma : Inglés (eng) Materias: Análisis de regresión
Lenguajes de programaciónPalabras clave: Mathematics Pharmacology Epidemiology Forestry Probabilities Statistics Computational intelligence Probability Theory and Stochastic Processes Statistical Methods Pharmacology/Toxicology Intelligence Clasificación: 004R R (Lenguaje de programación) Resumen: R is a rapidly evolving lingua franca of graphical display and statistical analysis of experiments from the applied sciences. Currently, R offers a wide range of functionality for nonlinear regression analysis, but the relevant functions, packages and documentation are scattered across the R environment. This book provides a coherent and unified treatment of nonlinear regression with R by means of examples from a diversity of applied sciences such as biology, chemistry, engineering, medicine and toxicology. The book begins with an introduction on how to fit nonlinear regression models in R. Subsequent chapters explain in more depth the salient features of the fitting function nls(), the use of model diagnostics, the remedies for various model departures, and how to do hypothesis testing. In the final chapter grouped-data structures, including an example of a nonlinear mixed-effects regression model, are considered. Christian Ritz has a PhD in biostatistics from the Royal Veterinary and Agricultural University. For the last 5 years he has been working extensively with various applications of nonlinear regression in the life sciences and related disciplines, authoring several R packages and papers on this topic. He is currently doing postdoctoral research at the University of Copenhagen. Jens C. Streibig is a professor in Weed Science at the University of Copenhagen. He has for more than 25 years worked on selectivity of herbicides and more recently on the ecotoxicology of pesticides and has extensive experience in applying nonlinear regression models. Together with the first author he has developed short courses on the subject of this book for students in the life sciences Nota de contenido: Getting Started -- Starting Values and Self-starters -- More on nls() -- Model Diagnostics -- Remedies for Model Violations -- Uncertainty, Hypothesis Testing, and Model Selection -- Grouped Data En línea: http://dx.doi.org/10.1007/978-0-387-09616-2 Link: https://biblioteca.cunef.edu/gestion/catalogo/index.php?lvl=notice_display&id=34144 Nonlinear Regression with R [documento electrónico] / SpringerLink (Online service) ; Christian Ritz ; Jens Carl Streibig . - New York, NY : Springer New York, 2008 . - XII, 148 p : online resource. - (Use R) .
ISBN : 978-0-387-09616-2
Idioma : Inglés (eng)
Materias: Análisis de regresión
Lenguajes de programaciónPalabras clave: Mathematics Pharmacology Epidemiology Forestry Probabilities Statistics Computational intelligence Probability Theory and Stochastic Processes Statistical Methods Pharmacology/Toxicology Intelligence Clasificación: 004R R (Lenguaje de programación) Resumen: R is a rapidly evolving lingua franca of graphical display and statistical analysis of experiments from the applied sciences. Currently, R offers a wide range of functionality for nonlinear regression analysis, but the relevant functions, packages and documentation are scattered across the R environment. This book provides a coherent and unified treatment of nonlinear regression with R by means of examples from a diversity of applied sciences such as biology, chemistry, engineering, medicine and toxicology. The book begins with an introduction on how to fit nonlinear regression models in R. Subsequent chapters explain in more depth the salient features of the fitting function nls(), the use of model diagnostics, the remedies for various model departures, and how to do hypothesis testing. In the final chapter grouped-data structures, including an example of a nonlinear mixed-effects regression model, are considered. Christian Ritz has a PhD in biostatistics from the Royal Veterinary and Agricultural University. For the last 5 years he has been working extensively with various applications of nonlinear regression in the life sciences and related disciplines, authoring several R packages and papers on this topic. He is currently doing postdoctoral research at the University of Copenhagen. Jens C. Streibig is a professor in Weed Science at the University of Copenhagen. He has for more than 25 years worked on selectivity of herbicides and more recently on the ecotoxicology of pesticides and has extensive experience in applying nonlinear regression models. Together with the first author he has developed short courses on the subject of this book for students in the life sciences Nota de contenido: Getting Started -- Starting Values and Self-starters -- More on nls() -- Model Diagnostics -- Remedies for Model Violations -- Uncertainty, Hypothesis Testing, and Model Selection -- Grouped Data En línea: http://dx.doi.org/10.1007/978-0-387-09616-2 Link: https://biblioteca.cunef.edu/gestion/catalogo/index.php?lvl=notice_display&id=34144 Ejemplares
Signatura Medio Ubicación Sub-localización Sección Estado ningún ejemplar
